Study S000098

SURE SPAIN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT04067999
Acronym: SURE SPAIN
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 230
Start: 2019-08-05
Primary completion: 2021-07-19
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1217-3546

Registered primary outcomes

Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]
Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.